cyclodecanylcarboxaldehyde | 91212-36-1

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机氧化物
• 英文名称: cyclodecanylcarboxaldehyde
• 英文别名: cyclodecanecarboxaldehyde；cyclodecane-aldehyde；Cyclodecan-carbaldehyd；Cyclodecanecarbaldehyde
• CAS: 91212-36-1
• 化学式: C₁₁H₂₀O
• 分子量: 168.279
• InChiKey: YTVHEWZXFAIRCL-UHFFFAOYSA-N

物化性质

• 沸点：
  113-115 °C(Press: 10 Torr)
• 密度：
  1.045 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-[(3S)-piperidin-3-ylmethyl]-2-(N-methyl-N-phenylamino)thiazole-4-carboxamide 、 cyclodecanylcarboxaldehyde 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 生成 N-[[(3S)-1-(cyclodecylmethyl)piperidin-3-yl]methyl]-2-(N-methylanilino)-1,3-thiazole-4-carboxamide
  参考文献：
  名称：

  Discovery of 2-Aminothiazole-4-carboxamides, a Novel Class of Muscarinic M3 Selective Antagonists, through Solution-Phase Parallel Synthesis

  摘要：

  描述了一类新的选择性抗美洲豹M3受体拮抗剂的合成和结构-活性关系。在寻找一种结构与2-(4,4-二氟环戊基)-2-苯乙酰胺衍生物不同的抗美洲豹M3受体拮抗剂的过程中，我们在内部化学库中识别出了一种噻唑-4-氨基甲酸酯衍生物（1）作为领先化合物。由于该化合物（1）在人体结合实验中对M3受体的结合亲和力较低（Ki=140 nM），我们尝试通过组合化学方法对1进行衍生化，以提高其对M3受体的效能和对M1及M2受体的选择性。溶液相平行合成有效地促进了1的每个片段的优化。因此，我们识别出环辛烯基甲基衍生物（3e）和环壬烯基甲基衍生物（3f）作为该类抗美洲豹M3受体选择性拮抗剂的代表。

  DOI：

  10.1248/cpb.53.437
• 作为产物：
  描述：

  methylenecyclodecane 在 过氧化氢苯甲酰 作用下， 以 氯仿 为溶剂， 生成 cyclodecanylcarboxaldehyde
  参考文献：
  名称：

  Addition Reactions with Methylenecyclodecane^1a,b

  摘要：

  DOI：

  10.1021/jo01056a049

文献信息

• Improved Conditions for the Proline-Catalyzed Aldol Reaction of Acetone with Aliphatic Aldehydes
  作者：Benjamin List、Alberto Martínez、Kristina Zumbansen、Arno Döhring、Manuel van Gemmeren

  DOI：10.1055/s-0033-1340919

  日期：——

  The proline-catalyzed asymmetric aldol reaction between aliphatic aldehydes and acetone has, to date, remained underdeveloped. Challenges in controlling this reaction include avoiding undesired side reactions such as aldol condensation and self-aldolization. In recent years we have developed optimized conditions, which enable high yields and good to excellent enantioselectivities, and which are presented

  迄今为止，脯氨酸催化的脂肪醛和丙酮之间的不对称醛醇反应仍未得到充分发展。控制该反应的挑战包括避免不希望的副反应，例如醛醇缩合和自醛醇化。近年来，我们开发了优化条件，可实现高产率和良好的对映选择性，并在本通讯中进行了介绍。
• [EN] ANTI-MICROBIAL AGENT-POLYMER CONJUGATES AND METHODS OF USE THEREOF<br/>[FR] CONJUGUÉS D'AGENT ANTIMICROBIEN-POLYMÈRE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV CALIFORNIA

  公开号：WO2018195078A1

  公开（公告）日：2018-10-25

  The present disclosure provides a conjugate comprising an anti-microbial agent and a hydrophilic polymer; and compositions, including pharmaceutical compositions, comprising the conjugates. The present disclosure provides a conjugate comprising a polymyxin covalently linked to a maltodextrin polymer; and compositions, including pharmaceutical compositions, comprising the conjugates. The present disclosure provides methods of inhibiting growth of a bacterium, and methods of treating a bacterial infection.

  本公开提供了一种包含抗微生物剂和亲水性聚合物的共轭物；以及包括药物组合物在内的组合物。本公开提供了一种包含共价连接到麦芽糖聚合物的多粘菌素的共轭物；以及包括药物组合物在内的组合物。本公开提供了抑制细菌生长的方法，以及治疗细菌感染的方法。
• DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS
  申请人：Matsuyama Hironori

  公开号：US20100004438A1

  公开（公告）日：2010-01-07

  An object of the present invention is to provide a medicinal drug much improved in anti tumor activity and excellent in safety. According to the present invention, there is provided a medicinal drug containing a compound represented by the following general formula (1) or a salt thereof as an active ingredient: [Formula 1] wherein X 1 represents a nitrogen atom or a group —CH═, R 1 represents a group -Z-R 6 , in which Z represents a group —CO—, a group —CH(OH)— or the like, R 6 represents a 5- to 15-membered monocyclic, dicyclic or tricyclic saturated or unsaturated heterocyclic group having 1 to 4 nitrogen atoms, oxygen atoms or sulfur atoms, R 2 represents a hydrogen atom or a halogen atom, Y represents a group —O—, a group —CO—, a group —CH(OH)— or a lower alkylene group, and A represents [Formula 2] wherein R 3 represents a hydrogen atom, a lower alkoxy group or the like, p represents 1 or 2, R 4 represents an imidazolyl lower alkyl group or the like.

  本发明的一个目的是提供一种在抗肿瘤活性方面大大改进且安全性优异的药物。根据本发明，提供了一种包含以下一般式（1）所表示的化合物或其盐作为活性成分的药物：[式1]其中X1代表氮原子或基团—CH═，R1代表一个基团-Z-R6，其中Z代表基团—CO—，基团—CH(OH)—或类似的基团，R6代表一个含有1至4个氮原子、氧原子或硫原子的5至15个成员的单环、双环或三环饱和或不饱和杂环基团，R2代表氢原子或卤原子，Y代表基团—O—，基团—CO—，基团—CH(OH)—或低碳烷基基团，A代表[式2]其中R3代表氢原子、低碳氧基基团或类似基团，p代表1或2，R4代表咪唑基低碳基团或类似基团。
• Pyrrolidine and thiazolidine compounds
  申请人：De Nanteuil Guillaume

  公开号：US20050261501A1

  公开（公告）日：2005-11-24

  Compounds of formula (I): wherein: X 1 represents an atom or group selected from CR 4a R 4b , O, S(O) q1 and NR 5 , wherein R 4a , R 4b , q 1 and R 5 are as defined in the description, m 1 represents zero or an integer from 1 to 4 inclusive, m 2 represents an integer from 1 to 4 inclusive, n 1 and n 2 , which may be identical or different, each represent an integer from 1 to 3 inclusive, R 1 represents hydrogen or a group selected from carboxy, alkoxycarbonyl, optionally substituted carbamoyl and optionally substituted alkyl, R 2 represents hydrogen or alkyl, Ak represents an optionally substituted alkylene chain, p represents zero, 1 or 2, R 3 represents hydrogen or cyano, X 2 and X 3 , which may be identical or different, each represent either S(O) q2 , or CR 6a R 6b , wherein q 2 , R 6a and R 6b are as defined in the description, its optical isomers, where they exist, and its addition salts with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful as DPP-IV inhibitors.

  式(I)化合物：其中：X1代表从CR4aR4b、O、S(O)q1和NR5中选择的原子或基团，其中R4a、R4b、q1和R5如描述中定义，m1表示零或从1到4的整数，m2表示从1到4的整数，n1和n2，可能相同也可能不同，每个代表从1到3的整数，R1代表氢或从羧基、烷氧羰基、可选地取代的氨基甲酰基和可选地取代的烷基中选择的基团，R2代表氢或烷基，Ak代表一个可选取代的烷基链，p表示零、1或2，R3代表氢或氰基，X2和X3，可能相同也可能不同，每个代表S(O)q2或CR6aR6b，其中q2、R6a和R6b如描述中定义，其光学异构体（如存在），以及与药学上可接受的酸形成的加合盐。含有这些化合物的药物产品，可用作DPP-IV抑制剂。
• Substituted piperidine compounds and methods of their use
  申请人：——

  公开号：US20040254218A1

  公开（公告）日：2004-12-16

  Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors.

  揭示了小说3,4-二取代-4-芳基哌啶化合物。还揭示了含有3,4-二取代-4-芳基哌啶化合物的药物组合物以及它们的药用方法。所揭示的化合物可用作阿片受体的拮抗剂，等等。